⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Official Title: Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer

Study ID: NCT03989362

Conditions

Cancer

Study Description

Brief Summary: JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.

Detailed Description: Vopratelimab (JTX-2011) is an agonist monoclonal antibody that specifically binds to the Inducible CO-Stimulator of T cells (ICOS) to generate an anti-tumor immune response. This is a Phase 2, open label study to evaluate the safety and efficacy of vopratelimab in combination with ipilimumab in adult subjects with advanced and/or refractory non-small cell lung cancer and urothelial cancer.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Beverly Hills Cancer Center, Beverly Hills, California, United States

University of Southern California Medical Center, Los Angeles, California, United States

Christiana Care Health Services, Newark, Delaware, United States

Florida Cancer Specialists Sarasota Cattlemen, Sarasota, Florida, United States

University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States

Massachusetts General Hospital, Boston, Massachusetts, United States

Washington University School of Medicine, Saint Louis, Missouri, United States

The Valley Hospital, Ridgewood, New Jersey, United States

Weill Cornell Medical College, New York, New York, United States

University of Rochester, Rochester, New York, United States

Southeastern Medical Oncology Center, Clinton, North Carolina, United States

Cleveland Clinic Foundation, Cleveland, Ohio, United States

Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, United States

Lifespan Cancer Institute, Providence, Rhode Island, United States

Vanderbilt University Medical Center, Nashville, Tennessee, United States

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

University of The Texas Health Science Center at San Antonio, San Antonio, Texas, United States

University of Virginia Health System, Charlottesville, Virginia, United States

University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada

The Research Institute of the McGill University Health, Montréal, Quebec, Canada

University Institute of Cardiology and Respirology of Quebec, Québec, , Canada

Contact Details

Name: Ellen Hooper, MD

Affiliation: Jounce Therapeutics, Inc.

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: